Anti-depressive mechanism of repetitive transcranial magnetic stimulation in rat: The role of the endocannabinoid system

Journal of Psychiatric Research

Volumn 51, Issue 1, 2014, Pages 79-87

  Wang, Hua ning ^a   Wang, Lei ^a,b   Zhang, Rui guo ^a   Chen, Yun chun ^a   Liu, Ling ^c   Gao, Fang ^c   Nie, Huang ^a   Hou, Wu gang ^a   Peng, Zheng wu ^a,c   Tan, Qingrong ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b SHANDONG MENTAL HEALTH CENTER   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cannabinoid type I receptor; Depression; Hippocampus; Repetitive transcranial magnetic stimulation

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; BRAIN DERIVED NEUROTROPHIC FACTOR; BROXURIDINE; CANNABINOID 1 RECEPTOR; PROTEIN BAX; PROTEIN BCL 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; CELL PROLIFERATION; CHRONIC STRESS; CONTROLLED STUDY; DENTATE GYRUS; DEPRESSION; FORCED SWIM TEST; IMMOBILITY; MALE; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPEAT PROCEDURE; REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION; SUCROSE PREFERENCE TEST; TRANSCRANIAL MAGNETIC STIMULATION; UPREGULATION;

CANNABINOID TYPE I RECEPTOR; DEPRESSION; HIPPOCAMPUS; REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION;

ANALYSIS OF VARIANCE; ANIMALS; BCL-2-ASSOCIATED X PROTEIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; BROMODEOXYURIDINE; CELL PROLIFERATION; DEPRESSION; DISEASE MODELS, ANIMAL; EXPLORATORY BEHAVIOR; FOOD PREFERENCES; GENE EXPRESSION REGULATION; HIPPOCAMPUS; MALE; PIPERIDINES; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; SWIMMING; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 84893906602     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2014.01.004     Document Type: Article

References (66)

1. Adamczyk P., Golda A., McCreary A.C., Filip M., Przegalinski E. Activation of endocannabinoid transmission induces antidepressant-like effects in rats. JPhysiol Pharmacol 2008, 59:217-228.
2. Almeida R.D., Manadas B.J., Melo C.V., Gomes J.R., Mendes C.S., Graos M.M., et al. Neuroprotection by BDNF against glutamate-induced apoptotic cell death is mediated by ERK and PI3-kinase pathways. Cell Death Differ 2005, 12:1329-1343.
3. Baeken C., De Raedt R., Leyman L., Schiettecatte J., Kaufman L., Poppe K., et al. The impact of one HF-rTMS session on mood and salivary cortisol in treatment resistant unipolar melancholic depressed patients. JAffect Disord 2009, 113:100-108.
4. Baeken C., De Raedt R., Bossuyt A., Van Hove C., Mertens J., Dobbeleir A., et al. The impact of HF-rTMS treatment on serotonin(2A) receptors in unipolar melancholic depression. Brain Stimul 2011, 4:104-111.
5. Ballmaier M., Bortolato M., Rizzetti C., Zoli M., Gessa G., Heinz A., et al. Cannabinoid receptor antagonists counteract sensorimotor gating deficits in the phencyclidine model of psychosis. Neuropsychopharmacology 2007, 32:2098-2107.
6. Benadhira R., Saba G., Samaan A., Dumortier G., Lipski H., Gastal D., et al. Transcranial magnetic stimulation for refractory depression. Am J Psychiatry 2005, 162:193.
7. Berlim M.T., Van den Eynde F., Daskalakis Z.J. Asystematic review and meta-analysis on the efficacy and acceptability of bilateral repetitive transcranial magnetic stimulation (rTMS) for treating major depression. Psychol Med 2012, 3:1-10.
8. Demitrack M.A., Thase M.E. Clinical significance of transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant depression: synthesis of recent data. Psychopharmacol Bull 2009, 42:5-38.
9. Denson T.F., Earleywine M. Decreased depression in marijuana users. Addict Behav 2006, 31:738-742.
10. Devane W.A., Dysarz F.A., Johnson M.R., Melvin L.S., Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988, 34:605-613.
11. Devlin J.T., Watkins K.E. Stimulating language: insights from TMS. Brain 2007, 130:610-622.
12. Dubreucq S., Koehl M., Abrous D.N., Marsicano G., Chaouloff F. CB1 receptor deficiency decreases wheel-running activity: consequences on emotional behaviours and hippocampal neurogenesis. Exp Neurol 2010, 224:106-113.
13. El Yacoubi M., Bouali S., Popa D., Naudon L., Leroux-Nicollet I., Hamon M., et al. Behavioral, neurochemical, and electrophysiological characterization of a genetic mouse model of depression. Proc Natl Acad Sci U S A 2003, 100:6227-6232.
14. Esser S.K., Huber R., Massimini M., Peterson M.J., Ferrarelli F., Tononi G. Adirect demonstration of cortical LTP in humans: a combined TMS/EEG study. Brain Res Bull 2006, 69:86-94.
15. Feng S.F., Shi T.Y., Fan Y., Wang W.N., Chen Y.C., Tan Q.R. Long-lasting effects of chronic rTMS to treat chronic rodent model of depression. Behav Brain Res 2012, 232:245-251.
16. Furtado C.P., Hoy K.E., Maller J.J., Savage G., Daskalakis Z.J., Fitzgerald P.B. An investigation of medial temporal lobe changes and cognition following antidepressant response: a prospective rTMS study. Brain Stimul 2013, 6:346-354.
17. George M.S., Wassermann E.M., Post R.M. Transcranial magnetic stimulation: a neuropsychiatric tool for the 21st century. JNeuropsychiatry Clin Neurosci 1996, 8:373-382.
18. George M.S., Nahas Z., Borckardt J.J., Anderson B., Foust M.J., Burns C., et al. Brain stimulation for the treatment of psychiatric disorders. Curr Opin Psychiatry 2007, 20:250-254. [discussion 247-259].
19. Gruber A.J., Pope H.G., Brown M.E. Do patients use marijuana as an antidepressant?. Depression 1996, 4:77-80.
20. Haghani M., Shabani M., Javan M., Motamedi F., Janahmadi M. CB1 cannabinoid receptor activation rescues amyloid beta-induced alterations in behaviour and intrinsic electrophysiological properties of rat hippocampal CA1 pyramidal neurones. Cell Physiol Biochem 2012, 29:391-406.
21. Hallett M. Transcranial magnetic stimulation: a primer. Neuron 2007, 55:187-199.
22. Hill M.N., Gorzalka B.B. Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression?. Behav Pharmacol 2005, 16:333-352.
23. Hill M.N., Gorzalka B.B. Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test. Eur Neuropsychopharmacol 2005, 15:593-599.
24. Hill M.N., Gorzalka B.B. Impairments in endocannabinoid signaling and depressive illness. JAMA 2009, 301:1165-1166.
25. Hill M.N., Patel S., Carrier E.J., Rademacher D.J., Ormerod B.K., Hillard C.J., et al. Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology 2005, 30:508-515.
26. Hill M.N., Carrier E.J., McLaughlin R.J., Morrish A.C., Meier S.E., Hillard C.J., et al. Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment. JNeurochem 2008, 106:2322-2336.
27. Hill M.N., Ho W.S., Hillard C.J., Gorzalka B.B. Differential effects of the antidepressants tranylcypromine and fluoxetine on limbic cannabinoid receptor binding and endocannabinoid contents. JNeural Transm 2008, 115:1673-1679.
28. Hill M.N., McLaughlin R.J., Bingham B., Shrestha L., Lee T.T., Gray J.M., et al. Endogenous cannabinoid signaling is essential for stress adaptation. Proc Natl Acad Sci U S A 2010, 107:9406-9411.
29. Hosohata Y., Quock R.M., Hosohata K., Makriyannis A., Consroe P., Roeske W.R., et al. AM630 antagonism of cannabinoid-stimulated [35S]GTP gamma S binding in the mouse brain. Eur J Pharmacol 1997, 321:R1-R3.
30. Huestis M.A., Gorelick D.A., Heishman S.J., Preston K.L., Nelson R.A., Moolchan E.T., et al. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry 2001, 58:322-328.
31. Janicak P.G., Nahas Z., Lisanby S.H., Solvason H.B., Sampson S.M., McDonald W.M., et al. Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study. Brain Stimul 2010, 3:187-199.
32. Jin Y., Lim C.M., Kim S.W., Park J.Y., Seo J.S., Han P.L., et al. Fluoxetine attenuates kainic acid-induced neuronal cell death in the mouse hippocampus. Brain Res 2009, 1281:108-116.
33. Keck M.E., Sillaber I., Ebner K., Welt T., Toschi N., Kaehler S.T., et al. Acute transcranial magnetic stimulation of frontal brain regions selectively modulates the release of vasopressin, biogenic amines and amino acids in the rat brain. Eur J Neurosci 2000, 12:3713-3720.
34. Kim J.J., Lee H.J., Welday A.C., Song E., Cho J., Sharp P.E., et al. Stress-induced alterations in hippocampal plasticity, place cells, and spatial memory. Proc Natl Acad Sci U S A 2007, 104:18297-18302.
35. Le Foll B., Gorelick D.A., Goldberg S.R. The future of endocannabinoid-oriented clinical research after CB1 antagonists. Psychopharmacology (Berl) 2009, 205:171-174.
36. Litvin Y., Phan A., Hill M.N., Pfaff D.W., McEwen B.S. CB1 receptor signaling regulates social anxiety and memory. Genes Brain Behav 2013, 12:479-489.
37. Lutz B. Endocannabinoid signals in the control of emotion. Curr Opin Pharmacol 2009, 9:46-52.
38. Malberg J.E., Eisch A.J., Nestler E.J., Duman R.S. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. JNeurosci 2000, 20:9104-9110.
39. Manji H.K., Chen G. PKC, MAP kinases and the bcl-2 family of proteins as long-term targets for mood stabilizers. Mol Psychiatry 2002, 7(Suppl.1):S46-56.
40. Manzanares J., Uriguen L., Rubio G., Palomo T. Role of endocannabinoid system in mental diseases. Neurotox Res 2004, 6:213-224.
41. Moldrich G., Wenger T. Localization of the CB1 cannabinoid receptor in the rat brain. An immunohistochemical study. Peptides 2000, 21:1735-1742.
42. Moreira F.A., Grieb M., Lutz B. Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. Best Pract Res Clin Endocrinol Metab 2009, 23:133-144.
43. O'Reardon J.P., Solvason H.B., Janicak P.G., Sampson S., Isenberg K.E., Nahas Z., et al. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry 2007, 62:1208-1216.
44. Padberg F., George M.S. Repetitive transcranial magnetic stimulation of the prefrontal cortex in depression. Exp Neurol 2009, 219:2-13.
45. Pertwee R.G. Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci 2005, 76:1307-1324.
46. Pertwee R.G., Griffin G., Lainton J.A., Huffman J.W. Pharmacological characterization of three novel cannabinoid receptor agonists in the mouse isolated vas deferens. Eur J Pharmacol 1995, 284:241-247.
47. Petrik D., Lagace D.C., Eisch A.J. The neurogenesis hypothesis of affective and anxiety disorders: are we mistaking the scaffolding for the building?. Neuropharmacology 2012, 62:21-34.
48. Post A., Keck M.E. Transcranial magnetic stimulation as a therapeutic tool in psychiatry: what do we know about the neurobiological mechanisms?. JPsychiatr Res 2001, 35:193-215.
49. Quesseveur G., David D.J., Gaillard M.C., Pla P., Wu M.V., Nguyen H.T., et al. BDNF overexpression in mouse hippocampal astrocytes promotes local neurogenesis and elicits anxiolytic-like activities. Transl Psychiatry 2013, 3:e253.
50. Rosenbrock H., Koros E., Bloching A., Podhorna J., Borsini F. Effect of chronic intermittent restraint stress on hippocampal expression of marker proteins for synaptic plasticity and progenitor cell proliferation in rats. Brain Res 2005, 1040:55-63.
51. Rutkowska M. The effect of am 251, a cannabinoid CB1 receptor antagonist, on food intake in rats. Acta Pol Pharm 2004, 61:401-403.
52. Shearman L.P., Rosko K.M., Fleischer R., Wang J., Xu S., Tong X.S., et al. Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice. Behav Pharmacol 2003, 14:573-582.
53. Shirayama Y., Chen A.C., Nakagawa S., Russell D.S., Duman R.S. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. JNeurosci 2002, 22:3251-3261.
54. Slattery D.A., Cryan J.F. Using the rat forced swim test to assess antidepressant-like activity in rodents. Nat Protoc 2012, 7:1009-1014.
55. Spennato G., Zerbib C., Mondadori C., Garcia R. Fluoxetine protects hippocampal plasticity during conditioned fear stress and prevents fear learning potentiation. Psychopharmacology (Berl) 2008, 196:583-589.
56. Tan T., Xie J., Liu T., Chen X., Zheng X., Tong Z., et al. Low-frequency (1Hz) repetitive transcranial magnetic stimulation (rTMS) reverses Abeta1-42-mediated memory deficits in rats. Exp Gerontol 2013, 48:786-794.
57. Wang Q., Peng Y., Chen S., Gou X., Hu B., Du J., et al. Pretreatment with electroacupuncture induces rapid tolerance to focal cerebral ischemia through regulation of endocannabinoid system. Stroke 2009, 40:2157-2164.
58. Wang H.Y., Crupi D., Liu J., Stucky A., Cruciata G., Di Rocco A., et al. Repetitive transcranial magnetic stimulation enhances BDNF-TrkB signaling in both brain and lymphocyte. JNeurosci 2011, 31:11044-11054.
59. Wang Q., Li X., Chen Y., Wang F., Yang Q., Chen S., et al. Activation of epsilon protein kinase C-mediated anti-apoptosis is involved in rapid tolerance induced by electroacupuncture pretreatment through cannabinoid receptor type 1. Stroke 2011, 42:389-396.
60. Wang Y., Xiao Z., Liu X., Berk M. Venlafaxine modulates depression-induced behaviour and the expression of Bax mRNA and Bcl-xl mRNA in both hippocampus and myocardium. Hum Psychopharmacol 2011, 26:95-101.
61. Wang Y., Liu X., Zhang D., Chen J., Liu S., Berk M. The effects of apoptosis vulnerability markers on the myocardium in depression after myocardial infarction. BMC Med 2013, 11:32.
62. Williamson E.M., Evans F.J. Cannabinoids in clinical practice. Drugs 2000, 60:1303-1314.
63. Willner P., Towell A., Sampson D., Sophokleous S., Muscat R. Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology (Berl) 1987, 93:358-364.
64. Wolf S.A., Bick-Sander A., Fabel K., Leal-Galicia P., Tauber S., Ramirez-Rodriguez G., et al. Cannabinoid receptor CB1 mediates baseline and activity-induced survival of new neurons in adult hippocampal neurogenesis. Cell Commun Signal 2010, 8:12.
65. Yang C.H., Huang C.C., Hsu K.S. Behavioral stress modifies hippocampal synaptic plasticity through corticosterone-induced sustained extracellular signal-regulated kinase/mitogen-activated protein kinase activation. JNeurosci 2004, 24:11029-11034.
66. Yue L., Xiao-Lin H., Tao S. The effects of chronic repetitive transcranial magnetic stimulation on glutamate and gamma-aminobutyric acid in rat brain. Brain Res 2009, 1260:94-99.